Therapeutic targeting of oncogenic K-ras by a covalent catalytic site inhibitor

Sang Min Lim, Kenneth D. Westover, Scott B. Ficarro, Rane A. Harrison, Hwan Geun Choi, Michael E. Pacold, Martin Carrasco, John Hunter, Nam Doo Kim, Ting Xie, Taebo Sim, Pasi A. Jänne, Matthew Meyerson, Jarrod A. Marto, John R. Engen, Nathanael S. Gray

Research output: Contribution to journalArticlepeer-review

247 Scopus citations

Abstract

We report the synthesis of a GDP analogue, SML-8-73-1, and a prodrug derivative, SML-10-70-1, which are selective, direct-acting covalent inhibitors of the K-Ras G12C mutant relative to wild-type Ras. Biochemical and biophysical measurements suggest that modification of K-Ras with SML-8-73-1 renders the protein in an inactive state. These first-in-class covalent K-Ras inhibitors demonstrate that irreversible targeting of the K-Ras guanine-nucleotide binding site is potentially a viable therapeutic strategy for inhibition of Ras signaling. Putting a stop to Ras: Two new selective, direct-acting covalent inhibitors of the K-Ras G12C mutant are reported. Studies suggest that the modification of K-Ras with SML-8-73-1 renders the protein inactive. These novel covalent inhibitors demonstrate that irreversible targeting of the K-Ras guanine-nucleotide binding site is potentially a viable therapeutic strategy for inhibition of Ras signaling.

Original languageEnglish (US)
Pages (from-to)199-204
Number of pages6
JournalAngewandte Chemie - International Edition
Volume53
Issue number1
DOIs
StatePublished - Jan 3 2014

Keywords

  • K-Ras
  • cancer
  • covalent inhibitors
  • drug design

ASJC Scopus subject areas

  • Catalysis
  • General Chemistry

Fingerprint

Dive into the research topics of 'Therapeutic targeting of oncogenic K-ras by a covalent catalytic site inhibitor'. Together they form a unique fingerprint.

Cite this